-
Product Insights
NewOropharyngeal Cancer – Drugs In Development, 2024
Empower your strategies with our Oropharyngeal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Oropharyngeal cancer is a disease in which malignant cells form in the tissue of oropharynx. The oropharynx is the middle part of the throat and includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types: HPV-positive, which are related to human papillomavirus infection; and HPV-negative cancers, which...
-
Product Insights
NewRecurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent head and neck squamous cell carcinoma (HNSCC) refers to the return of cancer in the head and neck region after initial treatment. HNSCC includes tumors of the oral cavity, pharynx, larynx, and other structures. Recurrence can occur locally, regionally, or distantly. Management of recurrent HNSCC depends on the specific circumstances, including the location and extent...
-
Track & Monitor
Consumer Goods Venture Capital Investments in Q3 2023
GlobalData's Consumer Goods VentureView report provides detailed coverage of the global venture capital investment activity in Consumer Goods industry in Q3 2023, covering key insights and trends.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BEY-1107 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEY-1107 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BEY-1107 in Metastatic Colorectal Cancer Drug Details:BEY-A is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OXI-4503 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OXI-4503 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.OXI-4503 in Relapsed Acute Myeloid Leukemia Drug Details:OXI-4503 (combretastatin A1 di-phosphate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Recurrent Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Recurrent Head And Neck Cancer...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Oropharyngeal Cancer Drug Details:NRC-2694 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Hypopharyngeal CancerDrug Details:NRC-2694 is under development for the treatment of recurrent...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Oral Cavity (Mouth) Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Oral Cavity (Mouth) Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Oral Cavity (Mouth) CancerDrug Details:NRC-2694 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NRC-2694 in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NRC-2694 in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NRC-2694 in Laryngeal CancerDrug Details:NRC-2694 is under development for the treatment of recurrent...